Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Jun;84(12):1602–1609. doi: 10.1054/bjoc.2001.1720

Pathological serosa and node-based classification accurately predicts gastric cancer recurrence risk and outcome, and determines potential and limitation of a Japanese-style extensive surgery for Western patients: A prospective with quality control 10-year follow-up study

D H Roukos 1,2, M Lorenz 1, K Karakostas 3, P Paraschou 4, C Batsis 2, A M Kappas 2
PMCID: PMC2363675  PMID: 11401312

Abstract

UICC classification accurately predicts overall survival but not recurrence-risk. We report here data of overall and first site-specific recurrence following curative surgery useful for the development of recurrence-oriented preventive target therapies. Patients who underwent resection for gastric cancer were stratified according to curability of surgery [curative (R0) vs non-curative resection], extent of surgery [limited (D1) vs extended (D2) node dissection] and pathological nodal/serosal status. The intent-to-treat principle, log-rank test and Cox regression analysis were used for statistical analysis of time-to-event (recurrence, death) endpoints. Curative resection only produced a chance of cure whereas survival was very poor following non-curative resection (P < 0.0001). For D2 R0 subgroup of patients, a pathological serosa and a node state-based classification into three groups, proved to be of clinical implication. Risk of recurrence after a median follow-up of 92 months was low among patients with both serosa and node-negative cancer (first group; 11%), moderate among those with either serosa or node-positive cancer (second group; 53%) and very high among those with both serosa and node-positive cancer (third group; 83%). In multivariate analysis, the relative risks of recurrence and death from gastric cancer among patients in the second and third groups, as compared to those in the first, were 7.07 (95% CI, 2.36–21.17;P  = 0.0002) and 16.19 (95% CI, 5.76–45.54;P < 0.0001) respectively. First site-specific recurrence analysis revealed: low rate of loco-regional recurrence alone (12%), serosa state determinant factor of the site-recurrence (peritoneal for serosa-positive and haematogenous for serosa-negative cancers) and dramatic increase of all types of recurrence by the presence of nodal metastases. Our findings demonstrate that a pathological serosa- and node-based classification is very simple and predicts accurately site-specific recurrence-risks. Furthermore they reveal that risk of recurrence following curative D2 surgery alone is low for serosa- and node-negative cancers, but very high in serosa- and node-positive cancers suggesting the need for new therapeutic strategies in this subgroup of patients. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: gastric cancer, extensive surgery, recurrence, survival, prognostic factors

Full Text

The Full Text of this article is available as a PDF (99.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Averbach A. M., Jacquet P. Strategies to decrease the incidence of intra-abdominal recurrence in resectable gastric cancer. Br J Surg. 1996 Jun;83(6):726–733. doi: 10.1002/bjs.1800830605. [DOI] [PubMed] [Google Scholar]
  2. Bonenkamp J. J., Hermans J., Sasako M., van de Velde C. J., Welvaart K., Songun I., Meyer S., Plukker J. T., Van Elk P., Obertop H. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999 Mar 25;340(12):908–914. doi: 10.1056/NEJM199903253401202. [DOI] [PubMed] [Google Scholar]
  3. Braun S., Pantel K., Müller P., Janni W., Hepp F., Kentenich C. R., Gastroph S., Wischnik A., Dimpfl T., Kindermann G. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med. 2000 Feb 24;342(8):525–533. doi: 10.1056/NEJM200002243420801. [DOI] [PubMed] [Google Scholar]
  4. Brennan M. F. Lymph-node dissection for gastric cancer. N Engl J Med. 1999 Mar 25;340(12):956–958. doi: 10.1056/NEJM199903253401210. [DOI] [PubMed] [Google Scholar]
  5. Bunt A. M., Hermans J., Smit V. T., van de Velde C. J., Fleuren G. J., Bruijn J. A. Surgical/pathologic-stage migration confounds comparisons of gastric cancer survival rates between Japan and Western countries. J Clin Oncol. 1995 Jan;13(1):19–25. doi: 10.1200/JCO.1995.13.1.19. [DOI] [PubMed] [Google Scholar]
  6. Cuschieri A., Weeden S., Fielding J., Bancewicz J., Craven J., Joypaul V., Sydes M., Fayers P. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer. 1999 Mar;79(9-10):1522–1530. doi: 10.1038/sj.bjc.6690243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fujii Masashi, Sasaki Juei, Nakajima Toshifusa. State of the art in the treatment of gastric cancer: from the 71st Japanese Gastric Cancer Congress. Gastric Cancer. 1999 Nov;2(3):151–157. doi: 10.1007/s101200050039. [DOI] [PubMed] [Google Scholar]
  8. Hermans J., Bonenkamp J. J., Boon M. C., Bunt A. M., Ohyama S., Sasako M., Van de Velde C. J. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol. 1993 Aug;11(8):1441–1447. doi: 10.1200/JCO.1993.11.8.1441. [DOI] [PubMed] [Google Scholar]
  9. Maehara Y., Hasuda S., Koga T., Tokunaga E., Kakeji Y., Sugimachi K. Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. Br J Surg. 2000 Mar;87(3):353–357. doi: 10.1046/j.1365-2168.2000.01358.x. [DOI] [PubMed] [Google Scholar]
  10. Maruyama K., Okabayashi K., Kinoshita T. Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg. 1987 Aug;11(4):418–425. doi: 10.1007/BF01655804. [DOI] [PubMed] [Google Scholar]
  11. Nakajima T., Nashimoto A., Kitamura M., Kito T., Iwanaga T., Okabayashi K., Goto M. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Gastric Cancer Surgical Study Group. Lancet. 1999 Jul 24;354(9175):273–277. doi: 10.1016/s0140-6736(99)01048-x. [DOI] [PubMed] [Google Scholar]
  12. Roukos D. H. Current status and future perspectives in gastric cancer management. Cancer Treat Rev. 2000 Aug;26(4):243–255. doi: 10.1053/ctrv.2000.0164. [DOI] [PubMed] [Google Scholar]
  13. Roukos D. H. Extended (D2) lymph node dissection for gastric cancer: do patients benefit? Ann Surg Oncol. 2000 May;7(4):253–255. doi: 10.1007/s10434-000-0253-0. [DOI] [PubMed] [Google Scholar]
  14. Roukos D. H., Hottenrott C., Lorenz M., Koutsogiorgas-Couchell S. A critical evaluation of effectivity of extended lymphadenectomy in patients with carcinoma of the stomach. An analysis of early results and long-term survival. J Cancer Res Clin Oncol. 1990;116(3):307–313. doi: 10.1007/BF01612909. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Roukos D. H., Lorenz M., Encke A. Evidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept: a prospective long-term follow-up study. Surgery. 1998 May;123(5):573–578. doi: 10.1067/msy.1998.88094. [DOI] [PubMed] [Google Scholar]
  16. Roukos D. H., Paraschou P., Lorenz M. Distal gastric cancer and extensive surgery: a new evaluation method based on the study of the status of residual lymph nodes after limited surgery. Ann Surg Oncol. 2000 Dec;7(10):719–726. doi: 10.1007/s10434-000-0719-0. [DOI] [PubMed] [Google Scholar]
  17. Siewert J. R., Böttcher K., Stein H. J., Roder J. D. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg. 1998 Oct;228(4):449–461. doi: 10.1097/00000658-199810000-00002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Wanebo H. J., Kennedy B. J., Chmiel J., Steele G., Jr, Winchester D., Osteen R. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg. 1993 Nov;218(5):583–592. doi: 10.1097/00000658-199321850-00002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Zippelius A., Pantel K. RT-PCR-based detection of occult disseminated tumor cells in peripheral blood and bone marrow of patients with solid tumors. An overview. Ann N Y Acad Sci. 2000 Apr;906:110–123. doi: 10.1111/j.1749-6632.2000.tb06600.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES